Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
Data from a large retrospective cohort study to be presented at the 2026 American Society of Clinical Oncology (ASCO) Breakthrough Meeting showed that GLP-1 receptor agonist (GLP-1 RA) use was significantly associated with lower colorectal cancer incidence among patients with inflammatory bowel disease (IBD), including those with comorbid type 2 diabetes (T2D)
The FDA has received adverse event reports, some requiring hospitalization, involving dosing errors in which patients administered five to twenty times their intended dose, due to unfamiliarity with vial-to-syringe measurement and confusion between units
you'll need to determine which weight loss plans are best suited to your unique health situation
Compare this to semaglutide results showing average losses of 10-15% body weight in clinical trials
GLP-1s might work better for some people than others
Whats more, if your B12 levels are adequate, adding B12 will not offer any benefits, including weight loss
